Recent developments in C5/C5a inhibitors
- 24 March 2006
- journal article
- Published by Taylor & Francis in Expert Opinion on Therapeutic Patents
- Vol. 16 (4), 445-458
- https://doi.org/10.1517/13543776.16.4.445
Abstract
Complement factor 5a (C5a) is formed upon complement system activation in response to infection, injury or disease. Whilst C5a is a potent mediator of immune and inflammatory processes, excessive production or inadequate regulation of C5a has been implicated in the pathogenesis of numerous immuno-inflammatory diseases, predominantly through experimental studies utilising animal models of disease. Both acute and chronic conditions may benefit from C5a inhibition, including rheumatoid arthritis, inflammatory bowel disease, asthma, psoriasis, haemorrhagic shock and neurodegenerative conditions. The potentially broad clinical application for treatments that inhibit the activity of C5a at C5a receptors and the large global market for anti-inflammatory therapeutics have made C5a and the C5a receptor attractive targets for academic and commercial drug development programmes. In the past 5 years, interest in C5a as a drug target has grown substantially, and this activity has resulted in a collection of patents and scientific papers reporting novel C5a and C5a receptor inhibitors and antagonists, and generated a secondary stream of patent applications broadly claiming the use of C5/C5a inhibitors as a method of treating various immune and inflammatory conditions. This paper will review the physiology and pathophysiology of C5a and discuss the development of C5a and C5a receptor inhibitors in light of the recent scientific and patent literature.Keywords
This publication has 98 references indexed in Scilit:
- The Structure of the C5a Receptor-blocking Domain of Chemotaxis Inhibitory Protein of Staphylococcus aureus is Related to a Group of Immune Evasive MoleculesJournal of Molecular Biology, 2005
- Increased Potency of a Novel Complement Factor 5a Receptor Antagonist in a Rat Model of Inflammatory Bowel DiseaseJournal of Pharmacology and Experimental Therapeutics, 2005
- Potent Cyclic Antagonists of the Complement C5a Receptor on Human Polymorphonuclear Leukocytes. Relationships between Structures and ActivityPublished by American Society for Pharmacology & Experimental Therapeutics (ASPET) ,2004
- Identification of a Potent and Orally Active Non-peptide C5a Receptor AntagonistPublished by Elsevier ,2002
- Mechanisms of Enhanced Lung Injury during SepsisThe American Journal of Pathology, 1999
- Effects of a new C5a receptor antagonist on C5a- and endotoxin- induced neutropenia in the ratBritish Journal of Pharmacology, 1999
- Decapeptide agonists of human C5a: the relationship between conformation and neutrophil responseJournal of Medicinal Chemistry, 1995
- Identification of a Receptor-Binding Region in the Core Segment of the Human Anaphylatoxin C5aJournal of Medicinal Chemistry, 1994
- Site‐specific mutagenesis of residues in the human C5a anaphylatoxin which are involved in possible interaction with the C5a receptorEuropean Journal of Biochemistry, 1994
- Tertiary structure of human complement component C5a in solution from nuclear magnetic resonance dataBiochemistry, 1989